Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study
Lists
Only you see this
Abstract
gov as #NCT03217812.
BibTeX
@inproceedings{fu2023bortezomib,
author = {Weijun Fu and Soo‐Mee Bang and Honghui Huang and Kihyun Kım and Wei Li and Gang An and Je‐Jung Lee and Zhen Cai and Jie Jin and Yafei Wang and Tung-Liang Lin and Chor Sang Chim and Ming Qi and Jianping Wang and Xiaolin Lü and Yang Song and Bin Jia and Xue Yang and Wenyu Liu and Tianyuan Zhou and Lu Yin and Yunan Li and Renyi Zhang and Jian Hou and Jianxiang Wang},
title = {{Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study}},
booktitle = {Clinical},
year = {2023},
doi = {10.1016/j.clml.2023.02.009},
}Loading related content...